



24 December 2024

Privatisation by way of merger

Disclosure of dealings in the shares of Shanghai Henlius Biotech, Inc. H Shares

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

Party	Date	Purchase / Sale	Number of shares	Price per share	Resultant balance (including those of any person with whom there is an agreement or understanding)	Percentage of class (including those of any person with whom there is an agreement or understanding)
Lin Lijun	24 December 2024	Purchase	420,000	\$23.9322	11,018,584	6.7421%

End

Note:

Lin Lijun is a Class (6) associate connec T4.9204 Tf1 0 0 1 757.68 22rinc3a22rinc3a22rin Tf